Rajan Sunil, Tosh Pulak, Kadapamannil Dilesh, Srikumar Soumya, Paul Jerry, Kumar Lakshmi
Department of Anaesthesiology and Critical Care, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
J Anaesthesiol Clin Pharmacol. 2018 Apr-Jun;34(2):193-197. doi: 10.4103/joacp.JOACP_263_17.
Hyponatremia is one of the most common electrolyte abnormality encountered in postoperative patients especially in the elderly. We aimed to assess the efficacy of single-dose intravenous conivaptan vs. oral tolvaptan therapy for correction of hyponatremia in postoperative patients.
This prospective randomized study was conducted on 40 patients aged 20-70 years, who had undergone major head and neck surgeries with a serum sodium level of ≤130 mEq/L and were symptomatic. Patients were randomly allocated into two equal groups. Patients belonging to group C received single intravenous bolus dose of conivaptan 20mg, whereas group T received oral tolvaptan 15mg on the first day. At 24h, if sodium correction was <4mEq/L, dose of tolvaptan was increased to 30mg in group T or an infusion of conivaptan 20mg over next 24h was started in group C.
Chi-square test, independent sample -test, and paired -test were used as applicable. Though there was no significant difference in the baseline sodium values in both groups, at 12 and 24 h group C had significantly high values. At 48h sodium values in both the groups were comparable. Intra-group analysis had shown that there was a significant increase in sodium values from the baseline at 12, 24, and 48 h in both the groups.
Single-dose intravenous conivaptan as well as oral tolvaptan were safe and effective in correcting hyponatremia in postoperative patients. Conivaptan could be considered superior as it resulted in faster sodium correction with effective aquaresis.
低钠血症是术后患者尤其是老年患者中最常见的电解质异常之一。我们旨在评估单剂量静脉注射考尼伐坦与口服托伐普坦治疗术后患者低钠血症的疗效。
本前瞻性随机研究对40例年龄在20 - 70岁之间、接受过重大头颈手术且血清钠水平≤130 mEq/L并有症状的患者进行。患者被随机分为两组。C组患者接受单次静脉推注20mg考尼伐坦,而T组患者在第一天接受口服15mg托伐普坦。24小时时,如果钠纠正幅度<4mEq/L,T组将托伐普坦剂量增加至30mg,或C组在接下来的24小时开始输注20mg考尼伐坦。
根据适用情况使用卡方检验、独立样本检验和配对检验。虽然两组的基线钠值无显著差异,但在12小时和24小时时C组的值显著更高。48小时时两组的钠值相当。组内分析表明,两组在12小时、24小时和48小时时钠值均较基线有显著升高。
单剂量静脉注射考尼伐坦和口服托伐普坦在纠正术后患者低钠血症方面均安全有效。考尼伐坦可被认为更具优势,因为它能更快速地纠正钠水平并实现有效的水清除。